Open AccessDocking Simulations and QM/MM Studies between Isoniazid Prodrug, Catalase‐Peroxidase (KatG) and S315T Mutant from Mycobacterium tuberculosis
Author(s) -
Elaine F. F. da Cunha,
Teodorico C. Ramalho,
Ricardo Bicca de Alencastro,
Elaine Rose Maia
Publication year - 2007
Publication title -
computational and mathematical methods in medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.462
H-Index - 48
eISSN - 1748-6718
pISSN - 1748-670X
DOI - 10.1080/17486700701374292
Subject(s) - isoniazid , mycobacterium tuberculosis , chemistry , mutant , prodrug , enzyme , docking (animal) , microbiology and biotechnology , biochemistry , tuberculosis , biology , medicine , nursing , gene , pathology
Isoniazid (INH), an antibiotic used to treat tuberculosis (TB), is a prodrug requiring activation by the Mycobacterium tuberculosis KatG (mtKatG). In the present work, theoretical calculations were carried out to locate the most energetically-favorable INH–KatG interaction modes using the experimental structure of a wild type and mutant mtKatG active site. The S315T mutation significantly affects the ability of the enzyme to convert INH to isonicotinic acid in vitro. The results showed that significant changes occur in the INH binding pattern when serine is replaced by threonine
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom